Cladribine tablets sustain remission through two treatment-free years
This extension of MAGNIFY-MS quantifies how durably no evidence of disease activity, cognition, and brain volume hold in relapsing multiple sclerosis after two short cladribine courses, informing counseling on treatment-free remission.
Cladribine tablets show promise for sustained treatment-free remission in RMS.
This study evaluates the long-term efficacy of cladribine tablets in maintaining remission and cognitive function in relapsing multiple sclerosis (RMS) without continuous treatment. After two years, 78.6% in Year 3 and 79.2% in Year 4 achieved no evidence of disease activity (NEDA-3). Cognitive function remained stable or improved in 79.0%/88.1% of participants. The findings suggest that cladribine tablets could offer a sustained treatment-free remission option for RMS, though its applicability to broader patient populations needs further investigation. Cladribine tablets maintained efficacy in RMS during treatment-free years 3 and 4.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?
Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.